Highlights
• $12M equity funding facility secured
• Second European patent secured for CVac™ ovarian cancer treatment
• Commencement of patient treatment with CVac™ Cancer Therapy Vaccine
• Completion of first Share Purchase Plan
• Continuing towards US FDA approvals process for CVac™
• Progressing commercialisation of CVac™ in Australia
• Success of fellow cancer immune-therapy development company, Nasdaq-listed
Dendreon
______________________________________________________________________________
- Forums
- ASX - By Stock
- IMM
- Ann: Appendix 4C - quarterly
IMM
immutep limited
Add to My Watchlist
4.00%
!
24.0¢

Ann: Appendix 4C - quarterly , page-6
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
24.0¢ |
Change
-0.010(4.00%) |
Mkt cap ! $350.4M |
Open | High | Low | Value | Volume |
25.0¢ | 25.0¢ | 24.0¢ | $258.4K | 1.058M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 183431 | 24.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
24.5¢ | 89680 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 183431 | 0.240 |
5 | 280782 | 0.235 |
11 | 295633 | 0.230 |
18 | 598700 | 0.225 |
18 | 1160504 | 0.220 |
Price($) | Vol. | No. |
---|---|---|
0.245 | 89680 | 7 |
0.250 | 461776 | 8 |
0.255 | 101128 | 6 |
0.260 | 166599 | 7 |
0.265 | 489742 | 5 |
Last trade - 16.10pm 10/07/2025 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |